Literature DB >> 17872814

Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?

Richard H Hunt1, Denis Choquette, Brian N Craig, Carlo De Angelis, Flavio Habal, Gordon Fulthorpe, John I Stewart, Alexander G G Turpie, Paul Davis.   

Abstract

OBJECTIVE: To provide family physicians and pharmacists with practical, evidence- and expertise-based guidance on choosing the safest approach to using analgesics to manage patients with musculoskeletal pain. SOURCES OF INFORMATION: Health care providers from family practice, rheumatology, gastroenterology, hepatology, internal medicine, and pharmacy participated in an educational needs assessment regarding the management of pain and the safety of commonly used analgesics. Feedback from one-on-one interviews was compiled and distributed to participants who selected key topics. Topics chosen formed the basis for the discussions of this multidisciplinary panel that reviewed data on the safety of analgesics, particularly in regard to comorbidity and concurrent use with other therapies. MAIN MESSAGE: Treatment should begin with an effective analgesic with the best safety profile at the lowest dose and escalate to higher doses and different analgesics as required. Acetaminophen is a safe medication that should be considered first-line therapy. Nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with potential adverse gastrointestinal, renal, hepatic, and cardiovascular effects. Physicians should not prescribe NSAIDs before taking a careful history and doing a physical examination so they have the information they need to weigh the risks (adverse effects and potential drug interactions) and benefits for individual patients.
CONCLUSION: Taking a complete and accurate history and doing a physical examination are essential for choosing the safest analgesic for a particular patient.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17872814      PMCID: PMC1949301     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  60 in total

1.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.

Authors:  F Catella-Lawson; M P Reilly; S C Kapoor; A J Cucchiara; S DeMarco; B Tournier; S N Vyas; G A FitzGerald
Journal:  N Engl J Med       Date:  2001-12-20       Impact factor: 91.245

2.  Pain as a reason to visit the doctor: a study in Finnish primary health care.

Authors:  P Mäntyselkä; E Kumpusalo; R Ahonen; A Kumpusalo; J Kauhanen; H Viinamäki; P Halonen; J Takala
Journal:  Pain       Date:  2001-01       Impact factor: 6.961

Review 3.  The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib.

Authors:  W C Maddrey; C J Maurath; K M Verburg; G S Geis
Journal:  Am J Ther       Date:  2000-05       Impact factor: 2.688

4.  Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies.

Authors:  L A García Rodríguez; S Hernández-Díaz; F J de Abajo
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

5.  An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.

Authors:  Hyman Tannenbaum; Claire Bombardier; Paul Davis; Anthony S Russell
Journal:  J Rheumatol       Date:  2005-12-01       Impact factor: 4.666

6.  Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series.

Authors:  T R Riley; J P Smith
Journal:  Am J Gastroenterol       Date:  1998-09       Impact factor: 10.864

7.  Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial.

Authors:  E K Kuffner; R C Dart; G M Bogdan; R E Hill; E Casper; L Darton
Journal:  Arch Intern Med       Date:  2001-10-08

8.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

9.  Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.

Authors:  Patricia M Kearney; Colin Baigent; Jon Godwin; Heather Halls; Jonathan R Emberson; Carlo Patrono
Journal:  BMJ       Date:  2006-06-03

Review 10.  Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.

Authors:  L Laine
Journal:  Gastroenterology       Date:  2001-02       Impact factor: 22.682

View more
  6 in total

1.  Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks.

Authors:  Carmelo Scarpignato; Angel Lanas; Corrado Blandizzi; Willem F Lems; Matthias Hermann; Richard H Hunt
Journal:  BMC Med       Date:  2015-03-19       Impact factor: 8.775

2.  Approach to the pharmacological management of chronic pain in patients with an alcohol use disorder.

Authors:  Laura Murphy; Karen Wk Ng; Victoria Ch Su; Sarah Woodworth-Giroux; Todd S Levy; Beth A Sproule; Andrea D Furlan
Journal:  J Pain Res       Date:  2015-11-30       Impact factor: 3.133

3.  Efficacy and safety of guaifenesin for upper back, neck, and shoulder pain: a Phase II proof-of-concept, multicenter, placebo-controlled, repeat-dose, parallel-group study.

Authors:  Agron Collaku; Yong Yue; Kenneth Reed
Journal:  J Pain Res       Date:  2017-03-21       Impact factor: 3.133

4.  Pain Bloc-R Alleviates Unresolved, Non-Pathological Aches and Discomfort in Healthy Adults-A Randomized, Double-Blind, Placebo-Controlled, Crossover Study.

Authors:  Malkanthi Evans; Abdul M Sulley; David C Crowley; Jamie Langston; Najla Guthrie
Journal:  Nutrients       Date:  2020-06-19       Impact factor: 5.717

Review 5.  Piroxicam-β-cyclodextrin: a GI safer piroxicam.

Authors:  C Scarpignato
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 6.  Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression.

Authors:  Carmelo Scarpignato; Luigi Gatta; Angelo Zullo; Corrado Blandizzi
Journal:  BMC Med       Date:  2016-11-09       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.